AveXis, Inc. was a big mover last session, as the company saw its shares rise above 15% on the day. The upside was due to continuation of the rally triggered by the announcement of Phase 1 trial of AVXS-101 in spinal muscular atrophy (SMA) Type 1. Also, this led to far more shares changing hands than in a normal session. This continues the recent uptrend for the company as the stock is now up over 41% in the past one-month time frame.
The company has seen no positive or negative estimate revision in the past 30 days. Also, its Zacks Consensus Estimate remained unchanged over the same timeframe. Friday’s price action is encouraging though, so make sure to keep a close watch on this firm in the near future.
AveXis currently carries a Zacks Rank #3 (Hold).
A better-ranked stock in the Medical – Biomedical and Genetics industry is Anthera Pharmaceuticals, Inc. (ANTH - Free Report) , which sports a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
Is AVXS going up? Or down? Predict to see what others think: Up or Down
Zacks' 2017 IPO Watch List
Before looking into the stocks mentioned above, you may want to get a head start on potential tech IPOs that are popping up on Zacks' radar. Imagine being in the first wave of investors to jump on a company with almost unlimited growth potential? This Special Report gives you the current scoop on 5 that may go public at any time.
One has driven from 0 to a $68 billion valuation in 8 years. Four others are a little less obvious but already show jaw-dropping growth. Download this IPO Watch List today for free >>